The Three Prime Repair Exonuclease 1 pipeline drugs market research report outlays comprehensive information on the Three Prime Repair Exonuclease 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Three Prime Repair Exonuclease 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Undisclosed which include the indications Solid Tumor, Unspecified Cancer, and Unspecified. It also reviews key players involved in Three Prime Repair Exonuclease 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Three Prime Repair Exonuclease 1 pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 5, and 1 respectively.
Three Prime Repair Exonuclease 1 overview
Three Prime Repair Exonuclease 1 (TREX1) is a cellular enzyme that plays a crucial role in maintaining genomic stability by participating in DNA repair processes. As a member of the exonuclease superfamily, TREX1 is primarily known for its involvement in DNA degradation and repair mechanisms. It is notable for its ability to function in the three prime-to-five prime direction, hydrolyzing DNA from its three prime end. One of the key functions of TREX1 is its participation in the resolution of aberrant DNA structures, such as those formed during DNA repair processes or arising from cellular stress. TREX1 is particularly involved in the removal of single-stranded DNA fragments, preventing their accumulation, which can lead to genomic instability and activation of the immune system. TREX1 has been associated with the regulation of immune responses, as mutations in the TREX1 gene have been linked to autoimmune disorders, including Aicardi-Goutières syndrome and systemic lupus erythematosus (SLE). In these conditions, dysfunctional TREX1 can result in the accumulation of cytoplasmic DNA, leading to an aberrant immune response and inflammation. Beyond its role in DNA repair and immune regulation, TREX1 has implications in various pathological conditions, including cancer. The dysregulation of TREX1 expression or activity may contribute to genomic instability, a hallmark of cancer development.
For a complete picture of Three Prime Repair Exonuclease 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
